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Brugada Syndrome
Since Brugada et al. published their ﬁrst paper in 1992 on the syndrome which became
known as Brugada syndrome, many papers have been published concerning the role of gene
SCN5A as its cause, along with studies on characteristic electrocardiographic ﬁndings,
mechanism of arrhythmia, aggravating factors and prognosis. Such studies gradually
clariﬁed the pathogenesis and clinical characteristics of this syndrome. However, SCN5A
variation is found only in 18–30% of Brugada syndrome patients.
Although the coved type pattern is thought to be important for correct diagnosis, it is
widely accepted that ﬂuctuation of the electrocardiographic patterns is one of the features
characteristic of Brugada syndrome. Sakabe et al. (Eur Heart J 2003; 24:1488-1493)
examined electrocardiographic ﬁndings in medical records representing 3,339 cases over
one to ten years, and they observed waveform changes between a saddle-back and coved
type in 56.5% among patients exhibiting Brugada-type electrocardiograms.
Implantation of an implantable cardioverter and deﬁbrillator (ICD) is the ﬁrst choice
treatment for patients with a history of cardiac events. But there is no agreement on
therapeutic policy for asymptomatic cases. Brugada et al. (Circulation 2003; 108:3092-
3096) have reported that the incidence of cardiac events observed during a period of 2729
months in 190 asymptomatic patients with Brugada syndrome was 8.4%. In the Sakabe’s
study there was only one patients who suﬀered a cardiac event and, moreover, all the
elctrocardiograms recorded at annual medial examinations over ten year period for this
patient were found to be the saddle-back type. However, a typical coved-type pattern was
recorded for the same patient immediately after an episode of ventricular ﬁbrillation
following the implantation of the ICD.
Few asymptomatic patients with Brugada type electrocardiograms who have no history
of cardiac events or family history of sudden cardiac death agree to undergo electro-
physiological examinations. It may be possible to prevent cardiac events in these patients if
their electrocardiograms normalize by oral administration of certain drugs. Recently, drugs
such as quinidine sulfate and phosphodiestrase III inhibitors have been reported to be
eﬀective in preventing cardiac events in Brugada syndrome. But the eﬃcacy of these drugs
for this indication has not yet been veriﬁed.
I would expect that the following problems such as the participation of gene variation
other than SCN5A in the origin of Brugada syndrome, the prognosis of the cases which show
saddle-back type Brugada electrocardiograms, and prevention of the cardiac events by
means of the oral administration of the drugs which can convert the Brugada type
electrocardiogram to the normal pattern, will be revealed in the near future.
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